Dario Campana

Campana Dario

Appointment(s)
  • Professor, Department of Paediatrics
Administrative Appointment(s)
  • Director, Director, Laboratory of Immunopathology and Cell Therapy, Division of Paediatric Haematology & Oncology, National University Health System
Academic Qualifications
  • PhD, University of Milano, Italy
  • MD, University of Torino, Italy
Research Interest(s)
  • Leukaemia
  • Lymphoma
  • Cancer Immunotherapy
Recent Publications
  • 1. Huang YJ, Coustan-Smith E, Kao HW, Liu HC, Chen SH, Hsiao CC, Yang CP, Jaing TH, Yeh TC, Kuo MC et al. 2017 Oct. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes. Journal of the Formosan Medical Association. 116(10):774-781. doi: 10.1016/j.jfma.2016.12.002.
  • 2. Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y et al. 2017 Jun. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. 129(25):3304-3313. doi: 10.1182/blood-2017-01-764324.
  • 3. Campana D, Pui CH. 2017 Apr. Minimal residual disease–guided therapy in childhood acute lymphoblastic leukemia. Blood. 129(14):1913-1918. doi: 10.1182/blood-2016-12-725804.
  • 4. Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE et al. 2017 Feb. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia. 31(2):333-339. doi:10.1038/leu.2016.234.
  • 5. Pui CH, Campana D. 2017 Jan. Minimal residual disease in pediatric ALL. Oncotarget. 8(45):78251-78252. doi: 10.18632/oncotarget.20856.